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Abstract
Background: Long noncoding RNAs (lncRNAs) have been proved to play important roles in the tumorigenesis and
development of human hepatocellular carcinoma (HCC). The aim of our study is to investigate the expression and
function of BRAF-activated noncoding RNA (BANCR) in HCC.
Methods: BANCR expression was detected in HCC tissues and cell lines by using quantitative real-time PCR
(qRT-PCR). Association between BANCR levels and clinicopathological factors and patient prognosis was also
analyzed. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), flow cytometry, and transwell invasion
and migration assays were used to investigate the role of BANCR in the regulation of biological behaviors of HCC
cells.
Results: BANCR expression was remarkably increased in HCC tissues compared with adjacent noncancerous tissues
(P < 0.001). BANCR expression in four HCC cell lines was also significantly upregulated (P < 0.05). Clinicopathologic
analysis revealed that high BANCR expression correlated with high tumor grade, large tumor size, venous
infiltration, advanced tumor, node, and metastasis (TNM) stage, and shorter overall survival. Multivariate regression
analysis identified BANCR overexpression as an independent unfavorable prognostic factor (relative risk [RR] 4.245;
P = 0.015) in HCC patients. Moreover, BANCR downregulation in Hep3B cells impaired cell proliferation, promoted
cell apoptosis, reduced cell invasion and migration, led to downregulated vimentin, and upregulated E-cadherin
protein levels.
Conclusions: These findings suggested that BANCR may contribute to HCC initiation and progression and would
be used as not only a novel prognostic marker but also a potential therapeutic target for this disease.
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Background
Hepatocellular carcinoma (HCC) is the fifth most
common cancer worldwide, with a constantly increas-
ing frequency, especially in China [1]. Despite recent
advances in clinical and experimental oncology, the
long-term prognosis of HCC patients remains poor,
due to late detection of disease, frequent cancer me-
tastasis, high recurrence rate, and lack of effective
therapeutic intervention for terminally staged tumors.
Previous studies have revealed many HCC-associated
deregulated genes and signaling pathways [2, 3], but
the highly complex molecular mechanisms underlying
its carcinogenesis and progression are still obscure.
Therefore, it is urgent to identify reliable biomarkers
of HCC for its early diagnosis, effective therapy, and
prognosis evaluation.
Long noncoding RNA (lncRNA), >200 nucleotides in
length, is a type of noncoding RNA molecule that can
regulate gene expression in transcriptional or posttran-
scriptional level [4, 5]. Recent research has shown that
lncRNAs participate in a large number of cellular pro-
cesses, such as cell proliferation, differentiation, apop-
tosis, and cell cycle progression [6]. Emerging evidence
indicates that lncRNAs play important roles in the biol-
ogy of human cancers, which may provide a new but
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promising way to deal with cancer [7]. Functional
lncRNAs may be applied for cancer diagnosis and prog-
nosis and also act as potential novel therapeutic targets.
For example, increased expression of lncRNA HOTTIP
enhances tumor growth and migration in pancreatic can-
cer [8]. LncRNA MALAT1 overexpression is a negative
prognostic factor for lung cancer [9]. LincRNAs VLDLR,
PVT1, and GAS5 could regulate tumor cell responses to
chemotherapy [10–12]. However, the understanding of
the expression and function of lncRNAs in HCC is still in
the early stage.
BRAF-activated noncoding RNA (BANCR), a 693-bp
lncRNA, was originally identified in melanoma cells by
Flockhart RJ et al. [13]. Subsequently, aberrant lncRNA
BANCR expression has been confirmed in papillary thy-
roid carcinoma [14], retinoblastoma [15], lung cancer
[16, 17], gastric cancer [18], and colorectal cancer [19].
In these tumors, BANCR regulated cell proliferation, mi-
gration, and invasion and may serve as a potential onco-
gene or a candidate tumor suppressor. However, no
report of BANCR in HCC has been found. In the
present study, we examined BANCR expression in HCC
tissues and cell lines. We also investigated the correl-
ation between BANCR levels and clinicopathological
characteristics and patient’s survival. Moreover, we ex-
plored the role of BANCR in the regulation of biological
behaviors of HCC cells.
Methods
Patients and clinical specimens
This study was approved by the Research Ethics
Committee of Qi-Lu Hospital. Written informed consent
was obtained from all of the patients. All specimens
were handled and made anonymous according to the
ethical and legal standards.
Matched fresh specimens of HCC and adjacent
noncancerous liver tissues were obtained from 109
patients who underwent hepatic resection at Qi-Lu
Hospital between January 2008 and March 2010. All
tissues were immediately frozen in liquid nitrogen
and stored at −80 °C until analysis. None of the pa-
tients had undergone chemotherapy or radiotherapy
before surgery. Details of clinical and pathological
characteristics of the patients are summarized in
Table 1. Follow-up data were available for all patients.
Overall survival was defined as the amount of time
from the day of primary surgery to the date of death
or the end of follow-up (for living patients).
Cell culture and RNA interference
Human HCC cell lines (HuH-7, Hep3B, HepG2, and
H2-M) and human normal hepatocyte CL-48 were ob-
tained from the Institute of Biochemistry and Cell Biol-
ogy of the Chinese Academy of Sciences (Shanghai,
China). The cells were maintained in high glucose
(4.5 g/l) Dulbecco’s modified Eagle’s medium (DMEM;
Gibco-BRL, Gaithersburg, MD) supplemented with 10 %
heat-inactivated fetal bovine serum (FBS), 100 U/ml of
penicillin and 100 μg/ml streptomycin sulfate. Cultures
were incubated in a humidified atmosphere of 5 % CO2
at 37 °C.
lncRNA BANCR small interfering RNA (si-BANCR)
and nontargeting small interfering RNA (siRNA) (si-NC)
were purchased from Sigma-Aldrich. HCC cells were
transfected with siRNA by using Lipofectamine 2000
(Invitrogen, CA, USA) according to the manufacturer’s
instructions. The cells were harvested for further assays
48 h after transfection.
RNA extraction, reverse transcription, and qRT-PCR
Total RNA was extracted using the Trizol reagent
(Invitrogen, Carlsbad, CA) according to the manufac-
turer’s instructions. RNA was reverse transcribed into
cDNA using the Prime-Script one step RT-PCR kit
(Takara, Dalian, China). BANCR expression levels were
measured with quantitative real-time PCR (qRT-PCR)
using an ABI7500 system and the SYBR Green PCR
Master Mix (Takara). Glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) was used as an internal control.
The primer sequences for BANCR were 5′-ACAGG
ACTCCATGGCAAACG-3′ (forward) and 5′-ATGAAG
AAAGCCTGGTGCAGT-3′ (reverse). Each assay was
performed in triplicate, and relative BANCR expression
was normalized to GAPDH using the 2−ΔCt method.
Cell proliferation assay
Cell proliferation was analyzed using MTT assay. Briefly,
approximately 1 × 103 cells were seeded into a 96-well
plate and incubated for 1, 2, 3, and 4 days. At the indi-
cated time point, 20 μl of MTT (5 mg/ml) (Sigma, USA)
was added into each well and incubated for another 4 h.
Then, the supernatants were removed, and 150 μl of
DMSO (Sigma, USA) was added to terminate the reac-
tion. The absorbance value (OD) was measured at
490 nm on a microplate reader (Molecular Devices,
Sunnyvale, CA, USA).
Detection of apoptosis by flow cytometry
Forty-eight hours after transfection, the HCC cells were
harvested, washed, and resuspended in ice-cold PBS.
The cells were then treated with propidium iodide
(10 μg/ml; Sigma) and Annexin V-FITC (50 μg/ml, BD)
in the dark for 15 min at room temperature and exam-
ined by flow cytometry (FACScan; BD Biosciences).
Cell invasion and migration assays
Six-well transwell chambers (8-μm pore size, Corning,
New York, USA) were used to investigate cell invasion
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Table 1 Correlation between BANCR expression and different clinicopathological features in patients with hepatocellular carcinoma
Clinicopathological features No. of cases BANCR expression P
Low (n, %) High (n, %)
Age
<60 53 29 (54.7 %) 24 (45.3 %) 0.845
≥60 56 26 (46.4 %) 30 (53.6 %)
Gender
Male 80 39 (48.8 %) 41 (51.2 %) 0.666
Female 29 16 (55.2 %) 13 (44.8 %)
Tumor grade
G1 34 24 (70.6 %) 10 (29.4 %) 0.007
G2 + G3 75 31 (41.3 %) 44 (58.7 %)
AFP (ng/L)
≥400 61 27 (44.4 %) 34 (55.6 %) 0.178
<400 48 28 (58.3 %) 20 (41.7 %)
With cirrhosis
Yes 74 36 (48.6 %) 38 (51.4 %) 0.683
No 35 19 (54.3 %) 16 (45.7 %)
Tumor diameter (cm)
<5 66 41 (62.1 %) 25 (37.9 %) 0.003
≥5 43 14 (32.6 %) 29 (67.4 %)
Tumor nodes
Multi 37 15 (40.5 %) 22 (59.5 %) 0.16
Single 72 40 (55.6 %) 32 (44.4 %)
Venous infiltration
Presence 39 11 (28.2 %) 28 (71.8 %) 0.001
Absence 70 44 (62.9 %) 26 (37.1 %)
TNM stage
I + II 51 34 (66.7 %) 17 (33.3 %) 0.002
III 58 21 (36.2 %) 37 (66.8 %)
Fig. 1 Relative BANCR expression levels in hepatocellular carcinoma (HCC) tissues and cell lines. BANCR expression was calculated by the 2−ΔCt
method and normalized to GAPDH. a BANCR expression was significantly higher in HCC tissues than in the corresponding noncancerous tissues.
b BANCR expression was upregulated in human HCC cell lines compared to normal hepatocyte CL-48O cells. *P < 0.05; **P< 0.01
Zhou and Gao World Journal of Surgical Oncology  (2016) 14:8 Page 3 of 8
and migration. For migration assay, about 1 × 105 HCC
cells in serum-free media were seeded into the upper
chambers after siRNA transfection. The lower cham-
ber contained medium with 20 % FBS to stimulate
migration. Following a 48 h-incubation, the cells lo-
cated on the lower surface of the chamber were fixed
with 95 % ethanol for 10 min, stained with 0.1 %
crystal violet for 20 min, and counted using a micro-
scope (Olympus Corp., Tokyo, Japan). For invasion
assay, the upper chambers were first covered with
5 mg/ml Matrigel, and the other steps were the same
as migration.
Western blot
Cells were lysed in RIPA buffer with protease inhibitors
and phosphatase inhibitors. The protein extracts were
loaded onto a 10 % sodium SDS-PAGE gel and trans-
ferred to a PVDF membrane. The blots were probed
with primary antibodies (Cell signal technology, USA)
followed by the HRP-conjugated secondary antibody.
Following three Tris-buffered saline containing 0.1 %
Tween-20 (TBST) washes, the membranes were devel-
oped using ECL Plus (Millipore, MA, USA) and exposed
to X-ray film. GAPDH served as the loading control.
Statistics
All statistical analyses were performed using the SPSS
16.0 software package (SPSS, Chicago, IL, USA). The
significance of differences between groups was estimated
by Student’s t test and chi-square test. Survival curves
were constructed with the Kaplan–Meier method and
compared by the log-rank test. The significance of sur-
vival variables was evaluated using a multivariate Cox
proportional hazards regression analysis. P < 0.05 was
considered statistically significant.
Results
Increased BANCR expression in HCC tissues and cell lines
BANCR expression in HCC tissues and cell lines was
measured by qRT-PCR. Figure 1a showed a significant
high expression of BANCR in HCC tissues compared
with adjacent noncancerous tissues (P < 0.001). BANCR
expression in four HCC cell lines was also clearly upreg-
ulated (Fig 1b, P < 0.05). The Hep3B cell line, which pos-
sessed the highest BANCR expression among all tested
cell lines, was chosen for the subsequent in vitro
experiments.
Association between clinicopathological characteristics
and BANCR expression in HCC patients
We further analyzed the association between BANCR
expression and clinicopathological characteristics of
HCC. HCC samples were classified into low BANCR ex-
pression group (n = 55) and the high BANCR expression
group (n = 54) according to the median BANCR expres-
sion level of all HCC samples. The association between
clinicopathological characteristics and BANCR expres-
sion was summarized in Table 1. We found that high
Fig. 2 Kaplan–Meier curves for overall survival of 109 hepatocellular
carcinoma patients, divided according to BANCR expression levels.
High BANCR expression was significantly associated with poor
survival (P < 0.001, log-rank test)
Table 2 Univariate and multivariate analysis of overall survival in 109 patients with hepatocellular carcinoma
Variables Univariate analysis Multivariate analysis
RR P value RR P value
Age (years) (≥60/<60) 0.785 0.323 – –
Gender (male/female) 0.721 0.455 – –
Tumor grade (G1/G2 + G3) 2.387 0.037 0.795 0.146
AFP (ng/l) (≥400/<400) 0.816 0.194 – –
With cirrhosis (yes/no) 0.904 0.092 – –
Tumor diameter (cm) (≥5/<5) 3.252 0.025 2.655 0.039
Tumor nodes (multi/single) 0.868 0.156 – –
Venous infiltration (presence/absence) 5.153 0.008 3.278 0.022
TNM stage (I–II/III) 6.225 <0.001 6.379 0.006
Expression of BANCR (low/high) 5.983 <0.001 4.245 0.015
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Fig. 3 (See legend on next page.)
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BANCR expression levels were closely correlated with
high tumor grade (P = 0.007), large tumor size (P =
0.003), venous infiltration (P = 0.001), and advanced
tumor, node, and metastasis (TNM) stage (P = 0.002).
No significant difference was observed between BANCR
expression and other clinical features such as patients’
age, gender, cirrhosis, serum AFP level, and number of
tumor nodules.
Prognostic values of BANCR expression in HCC patients
Then, we evaluated whether BANCR expression had
prognostic potential for overall survival of HCC patients.
Using the Kaplan–Meier method and log-rank test, the
overall survival of patients with high BANCR expression
was significantly shorter than those with low BANCR
expression (P < 0.001; Fig. 2). Besides, the survival bene-
fits were also found in those with small tumor diameter
(P = 0.025), well tumor differentiation (P = 0.037), nega-
tive venous invasion (P = 0.008), and early TNM stage
(P < 0.001; Table 2).
Multivariate Cox regression analysis enrolling the
abovementioned significant parameters revealed that
BANCR expression (relative risk [RR] 4.245; P = 0.015),
tumor size (RR 2.655; P = 0.039), venous infiltration (RR
3.278; P = 0.022), and TNM stage (RR 6.379; P = 0.006)
were independent prognostic markers for overall survival
of HCC patients (Table 2).
Effects of BANCR downregulation on the biological
behaviors of Hep3B cells
At last, we explored the role of BANCR in regulating the
biological behaviors of HCC cells. BANCR expression in
Hep3B cells was evidently downregulated after si-
BANCR transfection (Fig 3a). As shown in Fig. 3b, c,
BANCR downregulation impaired Hep3B cell prolifera-
tion and promoted cell apoptosis compared to the si-NC
group. In addition, the invasion and migration ability of
Hep3B cells was significantly reduced after si-BANCR
transfection (Fig 3d, e).
BANCR induces Epithelial-to-mesenchymal transition
(EMT) phenotypes
To explore the potential underlying mechanisms of
BANCR-related high cell migration, we detected the
changes in E-cadherin and vimentin protein levels after
si-BANCR transfection by Western blot. The results
showed that BANCR downregulation in Hep3B cells was
associated with upregulated E-cadherin and downregu-
lated vimentin protein levels (Fig. 4).
Discussion
Identifying novel molecules that take part in HCC for-
mation and progression may be helpful for improving
the diagnosis, prevention, and treatment of this disease.
The relationship between lncRNAs and tumors has cur-
rently become one of the focuses of cancer studies. Ab-
normal expression of several lncRNAs has been reported
in HCC. For example, lncRNA AOC4P overexpression
in HCC cells significantly reduced cell proliferation,
migration, and invasion by inhibiting the epithelial-
mesenchymal transition (EMT) [20]. lncRNA UCA1 was
aberrantly upregulated in HCC tissues and associated
with TNM stage, metastasis, and postoperative survival
[21]. UCA1 depletion inhibited the growth and metasta-
sis of HCC cell lines in vitro and in vivo. Serum
lncRNA-AF085935 was helpful to discriminate HCC
from hepatitis B viral infected patients and healthy con-
trols [22]. Injection of the lncRNA PTENP1-expressing
(See figure on previous page.)
Fig. 3 Effects of BANCR on the biological behaviors of Hep3B cells. a qRT-PCR analysis confirmed decreased BANCR expression in Hep3B cells
after si-BANCR transfecting. BANCR expression was normalized to GAPDH. *P < 0.05. b Cell proliferation was measured by MTT assay in Hep3B cells
transfected with si-BANCR or si-NC. **P < 0.01. c Flow cytometric analysis showed induced cell apoptosis after si-BANCR transfection. d, e Transwell
invasion and migration assays showed that the number of invaded/migrated cells was significantly lower in the si-BANCR-transfected group than
in the si-NC-transfected group. **P < 0.01
Fig. 4 BANCR downregulation in Hep3B cells was associated with decreased vimentin and increased E-cadherin protein levels
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vectors into mice bearing HCC tumors effectively miti-
gated the tumor growth, suppressed intratumoral cell
proliferation, elicited apoptosis, autophagy and inhibited
angiogenesis [23]. These findings suggested that
lncRNAs might play important roles in HCC initiation
and development and have a great potential for clinical
application.
In the present study, we observed a high BANCR ex-
pression in HCC specimens and cell lines, providing the
first evidence that BANCR overexpression was closely
associated with HCC carcinogenesis. Then, we corre-
lated increased BANCR levels with aggressive clinico-
pathological features of HCC tissues. Downregulation of
BANCR in Hep3B cells would reduce cell proliferation,
enhance cell apoptosis, and impair cell invasion and
migration. These findings revealed that BANCR might
be involved in HCC progression and contribute to
molecular-targeted therapy. In addition, our research
showed that HCC patients with high BANCR levels
tended to have shorter overall survival than patients with
lower levels. Multivariate Cox hazard regression analysis
identified high BANCR expression as an independent in-
dicator of unfavorable prognosis. To our knowledge, this
is the first study to analyze the expression and clinical
significance of BANCR in HCC.
BANCR has been reported as an oncogene in several
types of human malignancies. BANCR levels in human
malignant melanoma tissues increased with advanced
tumor stages, and the knockdown of BANCR suppressed
melanoma cell proliferation and migration through
MAPK pathway [13, 24]. BANCR overexpression corre-
lated with tumor stage and lymph node metastasis in
colorectal cancer and contributed to cancer cell migra-
tion through inducing epithelial-mesenchymal transition.
In gastric cancer, BANCR expression was increased in
tumor tissues compared with paired adjacent normal tis-
sues. High BANCR levels were positively associated with
clinical stage, tumor depth, lymph node and distant me-
tastasis, and poor prognosis [18]. In retinoblastoma,
BANCR regulated cell proliferation, migration, and inva-
sion in vitro and overexpressed BANCR expression
linked with tumor size, choroidal invasion, and optic
nerve invasion [15].
In contrast to the tumor-promoting properties men-
tioned above, Sun et al. reported that BANCR was obvi-
ously downregulated in non-small cell lung cancer tissues
and that reduced BANCR expression was associated with
larger tumor size, lymph node metastasis, advanced TNM
stage, and shorter overall survival. Ectopic expression of
BANCR impaired cell viability and invasion, leading to the
inhibition of metastasis in vitro and in vivo [16]. Taken to-
gether, the role of lncRNA BANCR in human malignan-
cies may be multifaceted and determined by the distinct
context in various microenvironments.
EMT is one of the key processes for primary tumor
cells to acquire a migratory capacity [25]. Reduced E-
cadherin expression and increased vimentin expression
are associated with HCC progression [26, 27]. Emerging
evidence demonstrates that lncRNAs, including
BANCR, may regulate EMT processes in several can-
cer types [19, 28–30]. In the present study, BANCR
downregulation resulted in upregulated E-cadherin
and downregulated vimentin protein levels. These
findings indicated that BANCR might be involved in
the regulation of EMT in HCC, providing a possible
explanation for BANCR-related high cell migration.
Conclusions
In conclusion, our research confirmed increased BANCR
expression in HCC tissues and cell lines. Our study also
showed that high BANCR levels correlated tumor pro-
gression and poor prognosis. Regulation of BANCR ex-
pression influenced biological behaviors of HCC cells.
These findings suggested that BANCR may act as an
oncogene in HCC initiation and development and would
be not only a novel prognostic marker but also a poten-
tial therapeutic target for this disease.
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